Intelligent Bio Solutions Inc. (INBS) NASDAQ
2.41
-0.04(-1.63%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.41
-0.04(-1.63%)
Currency In USD
| Previous Close | 2.45 |
| Open | 2.45 |
| Day High | 2.58 |
| Day Low | 2.39 |
| 52-Week High | 24.9 |
| 52-Week Low | 2.29 |
| Volume | 65,334 |
| Average Volume | 102,990 |
| Market Cap | 1.56M |
| PE | -0.17 |
| EPS | -14.45 |
| Moving Average 50 Days | 3.32 |
| Moving Average 200 Days | 9.17 |
| Change | -0.04 |
Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry
GlobeNewswire Inc.
Feb 25, 2026 1:45 PM GMT
Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with
Intelligent Bio Solutions Partners with Bouygues UK, Part of Multi-Billion Dollar Global Construction Giant Bouygues Construction, for UK Drug Testing Rollout
GlobeNewswire Inc.
Feb 24, 2026 1:45 PM GMT
Initial 13-site deployment with UK subsidiary of global construction firm employing 35,600 employees across 50+ countries, validates commercial scalability and ROI of INBS’s fingerprint drug testing technologyNEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE
Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
GlobeNewswire Inc.
Feb 05, 2026 1:30 PM GMT
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to d